Reata Pharmaceuticals Inc (NASDAQ:RETA)
| 90.82 Delayed Data As of 4:00pm ET |  +0.80 / +0.89%Today’s Change | 18.47 Today|||52-Week Range 95.00 | +139.06% Year-to-Date |
Latest RETA News | Press Releases
| Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates 5:15pm / Zacks.com - Paid Partner Content | Telesis Bio (TBIO) Reports Q4 Loss, Tops Revenue Estimates Mar 21 / Zacks.com - Paid Partner Content |
| Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates Mar 30 / Zacks.com - Paid Partner Content | 3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing Mar 19 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 90.02 |
| Today’s open | 89.22 |
| Day’s range | 88.05 - 93.07 |
| Volume | 37,611 |
| Average volume (3 months) | 1,165,650 |
| Market cap | $3.1B |
Data as of 4:00pm ET, 03/31/2023
Growth & Valuation
| Earnings growth (last year) | -4.32% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -80.71% |
| P/E ratio | NM |
| Price/Sales | 626.04 |
| Price/Book | -- |
Competitors
| ---- | ||
| ISEEIVERIC bio Inc | +0.55 | +2.29% |
| CYTKCytokinetics Inc | +0.98 | +2.86% |
| FOLDAmicus Therapeutics ... | +0.19 | +1.74% |
Data as of 4:00pm ET, 03/31/2023
Financials
| Last reporting date | March 31, 2023 |
| EPS forecast (this quarter) | -$2.35 |
| Annual revenue (last year) | $2.2M |
| Annual profit (last year) | -$311.9M |
| Net profit margin | -14,074.95% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Plano, Texas |
Forecasts
